EP
STIM icon

Essential Partners’s Neuronetics STIM Stock Holding History

Essential Partners’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09K Sell
835
-3,305
-80% -$4.81K ﹤0.01% 2207
2026
Q1 		$6K Buy
+4,140
New +$6.56K ﹤0.01% 1498

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Essential Partners's STIM Position: Q2 2026 in Review

Essential Partners reduced its Neuronetics (STIM) stake by 80% in Q2 2026, selling an estimated $4.81K and leaving 835 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Essential Partners first reported a position in STIM in Q1 2026 and has held it in 2 quarters since. The position peaked at $6K in Q1 2026. 86 funds tracked by Wall St. Rank hold STIM as of Q2 2026.

  • Essential Partners held 835 shares of Neuronetics worth $1.09K as of Q2 2026.
  • Essential Partners sold 3,305 Neuronetics shares in Q2 2026, an estimated $4.81K.
  • Neuronetics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2207 holding.
  • Essential Partners first reported a position in Neuronetics in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Neuronetics position peaked at $6K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Neuronetics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.